The Asia-Pacific Mitral & Tricuspid Valve-in-Valve/Valve-in-Ring Registry (AP ViV Registry)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21+
SponsorNational Heart Centre Singapore

About this trial

A retrospective and prospective, observational, multicenter cohort study of consecutive patients undergoing transcatheter mitral/tricuspid ViV or ViR procedure with balloon expandable valve across participating sites in Asia-Pacific.

Eligibility criteria

Qualifiers

Age ≥ 21

Had at least one documented Mitral valve-in-valve/valve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Mitral valve-in-valve/valve-in-ring procedure. (Prospective) OR Had at least one documented Tricuspid valve-in-valve/valve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Tricuspid valve-in-valve/valve-in-ring procedure. (Prospective)

Disqualifiers

Active endocarditis

Any other conditions which investigator deems unsuitable for participation.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

150 Participants
are grouped into 4 trial groups

Locations

8
Australia
John Hunter Hospital New Lambton Heights Australia
Hong Kong
Prince of Wales Hospital Hong Kong Hong Kong
Queen Elizabeth Hospital Hong Kong Hong Kong
India
MGM Healthcare Pvt Ltd ChennaiTamil Nadu, India

Sponsors and collaborators

National Heart Centre Singapore

Lead sponsor

Edwards Lifesciences

Collaborator